Pacira BioSciences

Pacira BioSciences

PCRX· Manufacturing· Fiscal year ends in December

CEO pay in FY2024Stock -44.2% in FY2024

Frank Lee is the CEO of Pacira BioSciences and was paid $15.9M in FY2024 (Dec).

Pay$100 in the stock at the end of FY23 → $56
CEO pay is from each Pacira BioSciences proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Executives8

See all
  1. 1Frank LeeFY2024
  2. 2Kristen WilliamsFY2024
  3. 3Daryl GauglerFY2024
  4. 4Jonathan SloninFY2024
  5. 5Shawn CrossFY2024
  6. 6Lauren RikerFY2024

Named executives and their total pay, from the Summary Compensation Table of the latest proxy.

Pay

See all

Pacira BioSciences paid its 8 named executives $32.2M in total in FY2024 (Dec). CEO Frank Lee was paid $15.9M of that.

Name
Frank LeeChief Executive OfficerNot disclosedNot disclosed
Kristen WilliamsChief Administrative Officer and Secretary
Daryl GauglerExecutive Vice President, Commercial Operations
Jonathan SloninChief Medical Officer
Shawn CrossChief Financial OfficerNot disclosedNot disclosed
Lauren RikerFormer Interim Chief Financial OfficerNot disclosedNot disclosed

of each named executive, from the Summary Compensation Table of each proxy.

Peers20

See all

The FY2023 (Dec) proxy of Pacira BioSciences names 20 peer companies for pay. Among Pacira BioSciences and these peers, CEO pay was 8th highest of 9 and total shareholder return was 6th highest of 9.

8th highest of 9in Pacira BioSciences and its pay peers, FY2023 (Dec) by CEO pay:

$3.1M$17.0M

6th highest of 9in Pacira BioSciences and its pay peers, FY2023 (Dec) by total shareholder return:

$56$250

The comes from the company's proxy. CEO pay and of each company come from its own Pay versus Performance table for the same fiscal year.

Board2

See all
  • Mark KronenfeldDirector · 10 yr on the boardIndependentCompensation, Nominating, Governance and Sustainability (Chair)—Paid as an executive
  • Christopher ChristieDirector · 4 yr on the boardIndependent—Paid as an executive

The board of the latest proxy (FY2023).

Activity

  1. Pay
    Pacira BioSciences Chief Administrative Officer and Secretary pay rose 125% to $3.6M. The stock fell 44% in FY2024 (Dec).
    DEF 14A
  2. Pay
    Pacira BioSciences Chief Medical Officer pay rose 81% to $2.9M. The stock fell 44% in FY2024 (Dec).
    DEF 14A
  3. Pay
    Pacira BioSciences Chief Medical Officer pay fell 11% to $1.9M. The stock fell 36% in FY2022 (Dec).
    DEF 14A
  4. Pay
    Pacira BioSciences Former CEO pay fell 89% to $727.4K. The stock fell 44% in FY2024 (Dec).
    DEF 14A
  5. Pay
    Pacira BioSciences Division head pay rose 134% to $3.6M. The stock fell 44% in FY2024 (Dec).
    DEF 14A
  6. Pay
    Pacira BioSciences Former CFO pay fell 10% to $1.3M. The stock fell 44% in FY2024 (Dec).
    DEF 14A
  7. Pay
    Pacira BioSciences Chief Administrative Officer and Secretary pay fell 20% to $1.6M. The stock fell 13% in FY2023 (Dec).
    DEF 14A
  8. Pay
    Pacira BioSciences Chief Medical Officer pay fell 15% to $1.6M. The stock fell 13% in FY2023 (Dec).
    DEF 14A
  9. Pay
    Pacira BioSciences Division head pay fell 33% to $1.5M. The stock fell 13% in FY2023 (Dec).
    DEF 14A
  10. Pay
    Pacira BioSciences Former CFO pay fell 18% to $1.4M. The stock fell 13% in FY2023 (Dec).
    DEF 14A

Filings5

See all
Annual report10-KFeb 26, 2026FY2025
Proxy statementDEF 14AApr 29, 2025FY2024
Annual report10-KFeb 27, 2025FY2024
Proxy statementDEF 14AApr 22, 2024FY2023
Annual report10-KFeb 29, 2024FY2023
For the press:Download CSVDownload PNGHow to use our data